Crossbow raises Series A funds to develop cancer antibodies
2023-07-12
疫苗免疫疗法
Preview
来源: Pharmaceutical Technology
Crossbow Therapeutics will use the funds to develop therapies to treat cancer. Credit: crystal light via Shutterstock.com.
Crossbow Therapeutics has raised Series A funds worth $80m to develop a new class of antibody treatments for cancer.
MPM BioImpact and Pfizer Ventures led the funding round, with Polaris Partners, BVF Partners and Eli Lilly and Company among others taking part.
Recommended Reports
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Vaccine For Oncology in Colorectal Cancer GlobalData
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Gene Therapy To Target Lewis Y Antigen For Lung Cancer in Lung Cancer GlobalData
View allCompanies IntelligenceEli Lilly and CoPolaris Partners LLCBVF Partners LPCrossbow CorpPfizer Ventures LLCView all
Proceeds will be used to progress the development of new therapies that act on peptide-loaded major histocompatibility complexes (pMHCs) present on cancer cells.
To target pMHCs, these therapies will leverage antibodies that imitate T-cell receptors (TCR-mimetics).
Such TCR-mimetics will be merged with off-the-shelf T-cell engagers and immunotherapies to create tumour-bolt (T-Bolt) molecules.
These T-Bolts can be tailored to treat a variety of cancers.
Crossbow Therapeutics CEO Briggs Morrison stated: “With unparalleled accuracy and potency, our revolutionary T-Bolt products strike cancer cells like a crossbow shoots bolts at its target.
“The influx of additional capital enables us to scale our efforts to build an arsenal of TCR-mimetic-based immunotherapies designed to overcome the limitations of current treatments.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
药物
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。